EICHORPublic-registry site landscape for NCT07678593, “A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation”, a Advanced Solid Tumors Cancer study sponsored by Genfleet Therapeutics (Shanghai) Inc.. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT07678593 (registry record) |
| Study title | A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation |
| Official title | A Multi-center, Open-label Phase Ib/II Study Exploring the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH276 in Combination With Cetuximab or Chemotherapy in the Treatment of Patients With Advanced Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation |
| Sponsor | Genfleet Therapeutics (Shanghai) Inc. |
| Condition(s) | Advanced Solid Tumors Cancer; Pancreatic Ductal Adenocarcinoma; RAS Mutation |
| Phase | PHASE1 / PHASE2 |
| Listed sites | 3 |
| Site countries | Australia, China |
Patient-friendly overview of this study: eichor.com/study/NCT07678593.
Eichor generates a preliminary site-risk snapshot for NCT07678593 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Advanced Solid Tumors Cancer trials
← Eichor home · All tracked trials · Advanced Solid Tumors Cancer studies · Weekly briefs
